Matsumoto Yoshihisa, Uehara Yuko, Mizushima Akio, Kosugi Toshifumi, Sone Miyuki, Nakamura Naoki, Miyashita Mitsunori, Morita Tatsuya, Yamaguchi Takuhiro, Satomi Eriko
Department of Palliative Therapy, Cancer Institute Hospital of Japanese Foundation for Cancer Research, Tokyo, Japan.
Department of Palliative Medicine, National Cancer Center Hospital East, Kashiwa, Japan.
Palliat Med Rep. 2024 Dec 9;5(1):543-552. doi: 10.1089/pmr.2024.0028. eCollection 2024.
Because of the limitations of pharmacological therapy, nonpharmacological therapies including intervention procedures are also important for quality of cancer pain management.
To clarify the availability of, number performed, barriers to performing, and educational practices of four interventional procedures (celiac plexus neurolysis/splanchnic nerve neurolysis, phenol saddle block, epidural analgesia, and intrathecal analgesia) in designated cancer hospitals.
Cross-sectional survey.
Designated cancer hospitals certified by the Japanese Government.
We administered self-administered questionnaires to collect general information about the facility and interventional procedures for refractory cancer pain between January and April 2021.
Questionnaires were sent to 402 facilities, and we received 199 valid responses (49.5%). Regarding availability, 36.7%-59.8% of the designated cancer hospitals reported that each procedure was available. Regarding the frequency of these procedures performed in the past 3 years, medians ranged from 1 to 4 times for each procedure. Among designated cancer hospitals, 44.7-65.8% reported the presence of barriers. Barriers such as "no/few physicians technically able to perform the procedure," "inability to follow-up after the procedure is implemented," and "the facilities to which patients may be referred after implementation are limited" were particularly pronounced. Training and treatment practice were provided by 30.7-55.8% of designated cancer hospitals for the procedures. Moreover, 12.6%-15.6% of designated cancer hospitals educated physicians and nurses responsible for cancer care in the region about pain treatment for the procedures.
Our findings suggest that designated cancer hospitals need to improve the availability, training, and education of interventional procedures.
由于药物治疗存在局限性,包括干预措施在内的非药物治疗对于癌症疼痛管理的质量也很重要。
明确指定癌症医院中四种干预措施(腹腔神经丛阻滞/内脏神经阻滞、酚甘油鞍区阻滞、硬膜外镇痛和鞘内镇痛)的可用性、实施数量、实施障碍以及教育实践情况。
横断面调查。
日本政府认证的指定癌症医院。
我们于2021年1月至4月发放了自填式问卷,以收集有关机构以及难治性癌症疼痛干预措施的一般信息。
向402家机构发放了问卷,共收到199份有效回复(49.5%)。关于可用性,36.7%-59.8%的指定癌症医院报告称每种措施均可用。关于这些措施在过去3年中的实施频率,每种措施的中位数为1至4次。在指定癌症医院中,44.7%-65.8%报告存在障碍。诸如“技术上能够实施该措施的医生没有/很少”“措施实施后无法进行随访”以及“实施后患者可能被转诊的机构有限”等障碍尤为突出。30.7%-55.8%的指定癌症医院针对这些措施提供了培训和治疗实践。此外,12.6%-15.6%的指定癌症医院对该地区负责癌症护理的医生和护士进行了有关这些措施疼痛治疗方面的教育。
我们的研究结果表明,指定癌症医院需要提高干预措施的可用性、培训和教育水平。